Colchicine

Generic Name: Colchicine

Brand Names: Colcrys, Gloperba, Lodoco, Mitigare

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅NO_₆

CAS Number: 64-86-8

Unique Ingredient Identifier: SML2Y3J35T

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.

Indication: Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.

Associated Conditions: Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke

Clinical Trials

Post-Ablation Pericarditis Reduction Study (PAPERS)

Phase 2

Completed

Conditions: Atrial Fibrillation
Catheter Ablation
Pericarditis

Interventions: Drug: Colchicine

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: St. Vincent Cardiovascular Research Institute

Target Recruit Count: 248

Registration Number: NCT06731595

Locations: 🇺🇸
Ascension St Vincent Hospital, Indianapolis, Indiana, United States

Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage

Phase 3

Not yet recruiting

Conditions: Colchicine
ICH - Intracerebral Hemorrhage
Stroke
Dependence

Interventions: Drug: Colchicine 0.5 MG
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-01-15

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 1125

Registration Number: NCT06587737

Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

Phase 4

Not yet recruiting

Conditions: Heart Failure
Heart Failure with Preserved Ejection Fraction (HFPEF)
Chronic Inflammation
Inflammation
Colchicine

Interventions: Drug: Colchicine 0.5 MG Oral Tablet Once Daily

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Dongying Zhang

Target Recruit Count: 200

Registration Number: NCT06604611

Locations: 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

The Effect of ColcHicine on the Incidence of Knee or Hip Replacements

Phase 3

Recruiting

Conditions: Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions: Drug: Colchicine
Drug: Placebo

First Posted Date: 2024-08-29

Last Posted Date: 2025-02-20

Lead Sponsor: Sint Maartenskliniek

Target Recruit Count: 1410

Registration Number: NCT06578182

Locations: 🇳🇱
Sint Maartenskliniek, Nijmegen, Netherlands

The Effect of Colchicine on Platelet Function Profiles in Patients With Stable Coronary Artery Disease

Phase 1

Recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Colchicine 0.5 MG oral tablet twice daily

First Posted Date: 2024-08-23

Last Posted Date: 2024-08-23

Lead Sponsor: The University of The West Indies

Target Recruit Count: 20

Registration Number: NCT06567678

Locations: 🇹🇹
The University of The West Indies, Saint Augustine, Trinidad and Tobago

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Phase 4

Recruiting

Conditions: Acute Coronary Syndrome

Interventions: Drug: Colchicine 0.6 mg

First Posted Date: 2024-08-07

Last Posted Date: 2024-08-09

Lead Sponsor: CHA University

Target Recruit Count: 490

Registration Number: NCT06543082

Locations: 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Efficacy and Safety of Colchicine After PCI

Phase 3

Recruiting

Conditions: Percutaneous Coronary Intervention
Colchicine
Coronary Heart Disease

Interventions: Drug: Placebo
Drug: Colchicine 0.5 mg
Drug: Colchicine 0.375 mg

First Posted Date: 2024-06-25

Last Posted Date: 2025-03-30

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 8862

Registration Number: NCT06472908

Locations: 🇨🇳
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China
🇨🇳
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

and more 33 locations